Details for New Drug Application (NDA): 050801
✉ Email this page to a colleague
The generic ingredient in EVOCLIN is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
Summary for 050801
Tradename: | EVOCLIN |
Applicant: | Norvium Bioscience |
Ingredient: | clindamycin phosphate |
Patents: | 2 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | AEROSOL, FOAM;TOPICAL | Strength | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Oct 22, 2004 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Feb 3, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Subscribe | Patent Expiration: | Jan 23, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF ACNE VULGARIS |
Expired US Patents for NDA 050801
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Norvium Bioscience | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | ⤷ Subscribe | ⤷ Subscribe |
Norvium Bioscience | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription